87512-31-0

Basic information

• Product Name: FMOC-ALA-ALA-OH
• Synonyms: Fmoc-L-Ala-L-Ala-OH;(S)-2-((S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)propanamido)propanoic acid;Fmoc-Ala-Ala-OH99%;FMOC-ALA-ALA-OH;FMOC-L-ALANYL-L-ALANINE;FMoc-AA-OH;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-alanyl-L-alanine;FMoc-Ala-Ala
• CAS NO: 87512-31-0
• Molecular Formula: C₂₁H₂₂N₂O₅
• Molecular Weight: 382.41
• Mol File: 87512-31-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 175-179℃ (ethyl acetate hexane )
• Boiling Point: 674.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.280±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.49±0.10(Predicted)
• CAS DataBase Reference: FMOC-ALA-ALA-OH(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-ALA-ALA-OH(87512-31-0)
• EPA Substance Registry System: FMOC-ALA-ALA-OH(87512-31-0)

Safety Data

• Hazardous Substances Data: 87512-31-0(Hazardous Substances Data)

Usage

General Description

FMOC-ALA-ALA-OH is a chemical compound used as a building block in the synthesis of peptides. It consists of three amino acids, specifically alanine, arranged in a chain and protected by a fluorenylmethyloxycarbonyl (FMOC) group. The FMOC group serves to protect the amino acids during peptide synthesis and can be easily removed in the final step. FMOC-ALA-ALA-OH is commonly used in solid-phase peptide synthesis as a precursor to create longer, more complex peptides with specific amino acid sequences. FMOC-ALA-ALA-OH is widely used in the research and development of pharmaceuticals and biochemistry due to its versatile applications in peptide chemistry.

Upstream product

• 1948-31-8 di-L-alanine 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 56-41-7 L-alanin 
• 73724-40-0 (S)-2,5-dioxopyrrolidin-1-yl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoate 
• 86060-86-8 (9H-fluoren-9-yl-methoxy)carbonyl-L-alanine pentafluorophenyl ester 
• 35661-39-3 N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine 
• 161009-04-7 N-α-(9-fluorenylmethoxycarbonyl)-di-L-alanine tert-butyl ester 
• 93709-88-7 Nα-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-L-alanine methyl ester 

Downstream Products

• 1438853-39-4 N^α-Fmoc-Ala-Ala-Asn(N-trityl)-PABC-PNP 
• 697805-40-6 C₅₁H₅₈FN₇O₁₀ 

Relevant articles and documents

Alaninyl variants of the marine natural product halocyamine A and their antibacterial properties

In an effort to explore the antibacterial potential of the marine natural product halocyamine A, a series of analogues including desbromo and alanine-substituted variants were synthesised and evaluated for biological activity against a panel of Gram-positive and –negative bacteria. The analogues were synthesised by a combination of solid-phase peptide synthesis and ruthenium complex/ytterbium triflate catalysed hydroamidation chemistry. Single alanine substitutions ([Ala1]-halocyamine A and [Ala2]-halocyamine A) gave only modest increases in activity towards Gram-positive bacteria, while di-alaninyl variants exhibited more potent activity with MIC values of 12.5–50 μM towards the Gram-positive bacteria Staphylococcus aureus and Enterococcus faecalis. A lipophilic trityl-protected intermediate of [Ala2]-halocyamine was the most active against the Gram-negative bacterium Escherichia coli.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

SPECIFICALLY ACTIVATED MICROMOLECULAR TARGET COUPLING BODY IN TUMOR MICROENVIRONMENT AND USE THEREOF

Provided are an anticancer compound comprising a cleavable linker specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is represented by the following formula, wherein, R1 is a normal functional group or a protection group; R2 is Ala, Thr, Val or Ile; R3 is Ala, Val or Asn; R4 is a drug group linked via a hydroxyl group or an amino group; and the general formula of the drug is R4H. The anticancer compound is only activated at a local portion of a tumor, thus avoiding the defect of immune system damage of a traditional chemotherapeutic drug, and promoting tumor immunization by removing a tumor immunosuppression cell. The anticancer compound or pharmaceutical composition thereof is jointly used with immunotherapy, thus improving the effect of treating the tumor, and effectively inhibiting tumor metastasis and osseous metastasis.